SCHEMBL2302718

SCHEMBL2302718

O=C1NCCN1c1ccc(S(=O)(=O)Nc2cccc(Br)c2)cc1

nearest known ligand 0.50

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
HTR6 P50406 4/20 0.50
HSD17B2 P37059 1/20 0.46
GAA P10253 1/20 0.45
POLB P06746 1/20 0.43
PKM P14618 1/20 0.43
ITGA1 P56199 1/20 0.42
TSHR P16473 1/20 0.42
TDP1 Q9NUW8 1/20 0.42
CYP19A1 P11511 1/20 0.42
NAMPT P43490 1/20 0.41
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
LMNA P02545 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
CA1 P00915 1/20 0.40
CA2 P00918 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2303492 0.86 MEN1 (0.58) HTR6GAAPKMTSHRCYP19A1
SCHEMBL12353997 0.86 LMNA (0.51) HTR6GAAPOLBPKMTSHR
SCHEMBL14239655 0.86 HTR6 (0.46) HTR6GAAPOLBPKMTSHR
SCHEMBL2301221 0.85 IDO1 (0.50) HTR6POLBPKMTSHRMEN1
SCHEMBL2299887 0.85 HTR6 (0.56) HTR6GAAPKMMEN1KMT2A
SCHEMBL2300250 0.83 PKM (0.60) HTR6PKMMEN1KMT2ALMNA
SCHEMBL2301616 0.83 LMNA (0.57) POLBPKMTSHRCYP19A1LMNA
SCHEMBL2302367 0.82 FFAR1 (0.50) HTR6GAAMEN1KMT2A
SCHEMBL2303199 0.80 LMNA (0.53) POLBPKMMEN1KMT2ALMNA
SCHEMBL2302292 0.80 PKM (0.67) GAAPOLBPKMMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9034888-B2 Substituted 2-imidazolidones and analogs UNIVERSITE LAVAL (CA) 2015-05-19 US disclosed
US-9034888-B2 Substituted 2-imidazolidones and analogs UNIVERSITE LAVAL (CA) 2015-05-19 US disclosed
US-9034888-B2 Substituted 2-imidazolidones and analogs UNIVERSITE LAVAL (CA) 2015-05-19 US disclosed
EP-2536693-A1 SUBSTITUTED 2-IMIDAZOLIDONES AND ANALOGS Université Laval (CA) 2012-12-26 EP disclosed
US-20120309777-A1 SUBSTITUTED 2-IMIDAZOLIDONES AND ANALOGS UNIVERSITE LAVAL (CA) 2012-12-06 US disclosed
US-20120309777-A1 SUBSTITUTED 2-IMIDAZOLIDONES AND ANALOGS UNIVERSITE LAVAL (CA) 2012-12-06 US disclosed
US-20120309777-A1 SUBSTITUTED 2-IMIDAZOLIDONES AND ANALOGS UNIVERSITE LAVAL (CA) 2012-12-06 US disclosed
WO-2011100840-A1 SUBSTITUTED 2-IMIDAZOLIDONES AND ANALOGS UNIVERSITé LAVAL (CA) 2011-08-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120309777-A1 SUBSTITUTED 2-IMIDAZOLIDONES AND ANALOGS CCNY, RPS4Y1, TPX2 HTR6 4117/4885HSD17B2 4706/4885GAA 3894/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.